CaseBioscience Joins $7.3 Million ARPA-H Initiative for Cell Therapy Preservation

CaseBioscience Inc. announced its participation in a team led by Likarda, which secured up to $7.3 million from ARPA-H's BioStabilization Systems (BoSS) program. This initiative aims to advance ambient preservation technologies for cell therapies, potentially making storage and transport easier and cheaper.

The RAB team, including CaseBioscience and other industry leaders, will explore innovative methods to maintain cell therapy viability at room temperature. This could reduce reliance on cold-chain logistics, making advanced therapies more accessible and affordable.

Dr. John Baust and Dr. Lynda McGinnis emphasized the program's potential to revolutionize biologics distribution. The project builds on CaseBioscience's expertise in cell biology and preservation.

CaseBioscience's role in this effort underlines its position in pioneering solutions to major challenges in biomedicine. The BoSS program's first phase has commenced, marking the start of a pivotal development period.